Cavernous sinus thrombosis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Raviteja Reddy Guddeti (talk | contribs)
nocaptcha
20,348 edits
Created page with "__NOTOC__ {{Cavernous sinus thrombosis}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. == Re..."
 
M Jahan (talk | contribs)
nocaptcha
2,881 edits
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 2: Line 2:
{{Cavernous sinus thrombosis}}
{{Cavernous sinus thrombosis}}


Please help WikiDoc by adding more content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.
{{CMG}}; {{AE}}{{MMJ}}
==Overview==
The prevalence of cavernous sinus thrombosis is approximately 1.32–1.57 per 100,000 individuals worldwide. The mortality rate of cavernous sinus thrombosis is approximately 20%. The combination of [[anticoagulants]] with antibiotics in treatment of cavernous sinus thrombosis has significantly decreased the mortality rate of it. Patients of all age groups may develop cavernous sinus thrombosis. The incidence of cavernous sinus thrombosis significantly increases with age. women are more commonly affected by cavernous sinus thrombosis than men. The women to men ratio is approximately 3.7–5.3 to 1.


== References ==
==Epidemiology and Demographics==
===Incidence===
*The prevalence of cavernous sinus thrombosis is approximately 1.32–1.57 per 100,000 individuals worldwide.<ref name="pmid27435401">{{cite journal| author=Devasagayam S, Wyatt B, Leyden J, Kleinig T| title=Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study. | journal=Stroke | year= 2016 | volume= 47 | issue= 9 | pages= 2180-2 | pmid=27435401 | doi=10.1161/STROKEAHA.116.013617 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27435401  }} </ref><ref name="pmid29441008">{{cite journal| author=Luo Y, Tian X, Wang X| title=Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review. | journal=Front Aging Neurosci | year= 2018 | volume= 10 | issue=  | pages= 2 | pmid=29441008 | doi=10.3389/fnagi.2018.00002 | pmc=5797620 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29441008  }} </ref>
===Case-fatality rate/Mortality rate===
 
*The mortality rate of cavernous sinus thrombosis is approximately 20%.<ref name="pmid27781123">{{cite journal| author=Arian M, Kamali A, Tabatabaeichehr M, Arashnia P| title=Septic Cavernous Sinus Thrombosis: A Case Report. | journal=Iran Red Crescent Med J | year= 2016 | volume= 18 | issue= 8 | pages= e34961 | pmid=27781123 | doi=10.5812/ircmj.34961 | pmc=5068248 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27781123  }} </ref>
The combination of [[anticoagulants]] with antibiotics in treatment of cavernous sinus thrombosis has significantly decreased the mortality rate of it.<ref name="pmid24842357">{{cite journal| author=Leo QJ, Bolger DT| title=Septic cavernous sinus thrombosis due to Campylobacter rectus infection. | journal=BMJ Case Rep | year= 2014 | volume= 2014 | issue=  | pages=  | pmid=24842357 | doi=10.1136/bcr-2013-203351 | pmc=4039913 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24842357  }} </ref>
===Age===
*Patients of all age groups may develop cavernous sinus thrombosis.
*The incidence of cavernous sinus thrombosis significantly increases with age.<ref name="pmid24842357">{{cite journal| author=Leo QJ, Bolger DT| title=Septic cavernous sinus thrombosis due to Campylobacter rectus infection. | journal=BMJ Case Rep | year= 2014 | volume= 2014 | issue=  | pages=  | pmid=24842357 | doi=10.1136/bcr-2013-203351 | pmc=4039913 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24842357  }} </ref><ref name="pmid24864625">{{cite journal| author=Karadas S, Milanlioglu A, Gönüllü H, Sayin R, Aydin MN| title=Cerebral venous sinus thrombosis presentation in emergency department in Van, Turkey. | journal=J Pak Med Assoc | year= 2014 | volume= 64 | issue= 4 | pages= 370-4 | pmid=24864625 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24864625  }} </ref>
 
===Gender===
*Women are more commonly affected by cavernous sinus thrombosis than men. The women to men ratio is approximately 3.7–5.3 to 1.<ref name="pmid29441008">{{cite journal| author=Luo Y, Tian X, Wang X| title=Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review. | journal=Front Aging Neurosci | year= 2018 | volume= 10 | issue=  | pages= 2 | pmid=29441008 | doi=10.3389/fnagi.2018.00002 | pmc=5797620 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29441008  }} </ref><ref name="pmid24864625">{{cite journal| author=Karadas S, Milanlioglu A, Gönüllü H, Sayin R, Aydin MN| title=Cerebral venous sinus thrombosis presentation in emergency department in Van, Turkey. | journal=J Pak Med Assoc | year= 2014 | volume= 64 | issue= 4 | pages= 370-4 | pmid=24864625 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24864625  }} </ref>
 
==References==
{{Reflist|2}}
{{Reflist|2}}


{{WikiDoc Help Menu}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Needs content]]
[[Category: (name of the system)]]
[[Category:Disease]]
[[Category:Neurology]]
[[Category:Hematology]]

Latest revision as of 16:54, 16 July 2018

Cavernous sinus thrombosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cavernous sinus thrombosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cavernous sinus thrombosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cavernous sinus thrombosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cavernous sinus thrombosis epidemiology and demographics

CDC on Cavernous sinus thrombosis epidemiology and demographics

Cavernous sinus thrombosis epidemiology and demographics in the news

Blogs on Cavernous sinus thrombosis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Cavernous sinus thrombosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Overview

The prevalence of cavernous sinus thrombosis is approximately 1.32–1.57 per 100,000 individuals worldwide. The mortality rate of cavernous sinus thrombosis is approximately 20%. The combination of anticoagulants with antibiotics in treatment of cavernous sinus thrombosis has significantly decreased the mortality rate of it. Patients of all age groups may develop cavernous sinus thrombosis. The incidence of cavernous sinus thrombosis significantly increases with age. women are more commonly affected by cavernous sinus thrombosis than men. The women to men ratio is approximately 3.7–5.3 to 1.

Epidemiology and Demographics

Incidence

  • The prevalence of cavernous sinus thrombosis is approximately 1.32–1.57 per 100,000 individuals worldwide.[1][2]

Case-fatality rate/Mortality rate

  • The mortality rate of cavernous sinus thrombosis is approximately 20%.[3]

The combination of anticoagulants with antibiotics in treatment of cavernous sinus thrombosis has significantly decreased the mortality rate of it.[4]

Age

  • Patients of all age groups may develop cavernous sinus thrombosis.
  • The incidence of cavernous sinus thrombosis significantly increases with age.[4][5]

Gender

  • Women are more commonly affected by cavernous sinus thrombosis than men. The women to men ratio is approximately 3.7–5.3 to 1.[2][5]

References

  1. ↑ Devasagayam S, Wyatt B, Leyden J, Kleinig T (2016). "Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study". Stroke. 47 (9): 2180–2. doi:10.1161/STROKEAHA.116.013617. PMID 27435401.
  2. ↑ 2.0 2.1 Luo Y, Tian X, Wang X (2018). "Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review". Front Aging Neurosci. 10: 2. doi:10.3389/fnagi.2018.00002. PMC 5797620. PMID 29441008.
  3. ↑ Arian M, Kamali A, Tabatabaeichehr M, Arashnia P (2016). "Septic Cavernous Sinus Thrombosis: A Case Report". Iran Red Crescent Med J. 18 (8): e34961. doi:10.5812/ircmj.34961. PMC 5068248. PMID 27781123.
  4. ↑ 4.0 4.1 Leo QJ, Bolger DT (2014). "Septic cavernous sinus thrombosis due to Campylobacter rectus infection". BMJ Case Rep. 2014. doi:10.1136/bcr-2013-203351. PMC 4039913. PMID 24842357.
  5. ↑ 5.0 5.1 Karadas S, Milanlioglu A, Gönüllü H, Sayin R, Aydin MN (2014). "Cerebral venous sinus thrombosis presentation in emergency department in Van, Turkey". J Pak Med Assoc. 64 (4): 370–4. PMID 24864625.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Cavernous_sinus_thrombosis_epidemiology_and_demographics&oldid=1482745"